Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

DISEASE CHARACTERISTICS:

* Histologically confirmed CD20-positive non-Hodgkin lymphoma

  * Relapsed, resistant, or chemorefractory disease
* Must have an available HLA-identical sibling donor
* No significant skin breakdown from tumor or other disease

PATIENT CHARACTERISTICS:

* ECOG performance status 0-2
* DLCO ≥ 50% of normal
* No symptomatic obstructive or restrictive pulmonary disease
* Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 60 mL/min
* Direct bilirubin ≤ 2.0 mg/dL (even if attributable to disease)
* SGOT and SGPT ≤ 2.5 times normal (even if attributable to disease)
* No history of severe hepatic dysfunction
* No severe cardiac dysfunction
* LVEF ≥ 50% by gated blood pool scan
* No major heart disease
* Patients with congenital or acquired heart disease or cardiac arrhythmias must undergo a cardiology consultation and evaluation
* No active infections

  * Patients who have not been seen and evaluated by a dentist for teeth cleaning and examination for potential sources of infection are ineligible
* HIV antibody negative
* No uncompensated major thyroid or adrenal dysfunction
* Not pregnant or nursing
* Persistently elevated systolic blood pressure (BP) ≥ 130 mm Hg or diastolic BP ≥ 80 mm Hg must be controlled with antihypertensive agents for at least 7 days prior to initiation of cell therapy

  * Patients with essential hypertension that is controlled with medication are eligible

PRIOR CONCURRENT THERAPY:

* Prior total dose of doxorubicin or daunorubicin must have been less than 450 mg/m\^2 unless an endomyocardial biopsy shows less than grade 2 drug effect
* No concurrent nitroglycerin preparations for angina pectoris
* No antiarrhythmic drugs for major ventricular dysrhythmias